Orladeyo Berotralstat Synthesis and Crystalline Salt Process Patents
The synthesis of berotralstat, the active ingredient in Orladeyo, involves specific chemical processes that are protected by patents. These patents often cover not only the molecule itself but also the methods used to manufacture it and the specific crystalline forms, or salts, that are produced. These crystalline forms can influence a drug's stability, solubility, and bioavailability.
What are the key patents for Orladeyo's berotralstat?
The patent landscape for berotralstat is complex and includes patents related to its synthesis, crystalline forms, and therapeutic uses. DrugPatentWatch.com tracks these patents, which are crucial for understanding market exclusivity and potential generic entry. The specific patents covering the synthesis and crystalline salt processes for berotralstat are detailed in patent filings and can be accessed through patent databases [1].
How are crystalline salt forms important for berotralstat?
Crystalline salt forms are vital in pharmaceutical development because they can significantly impact a drug's physical and chemical properties. For berotralstat, specific crystalline forms may offer advantages in terms of manufacturing efficiency, storage stability, and how effectively the drug is absorbed by the body. Patenting these specific forms helps protect the innovator company's investment in optimizing the drug's delivery and performance [2].
When do Orladeyo's berotralstat synthesis and salt process patents expire?
The expiration dates of patents for drug synthesis and crystalline forms determine when generic manufacturers can potentially enter the market. These dates can vary depending on the specific patent and any extensions or legal challenges. Information on patent expiry for berotralstat can be found through resources like DrugPatentWatch.com [1]. Understanding these timelines is critical for estimating when generic versions of Orladeyo might become available.
Can generic manufacturers challenge berotralstat's synthesis or salt process patents?
Generic drug manufacturers may challenge existing patents if they believe the patents are invalid or if they can develop a non-infringing synthesis or crystalline form. Such challenges can lead to legal battles that may alter the timeline for generic market entry. The specific strategies employed by generic companies often depend on the strength and scope of the innovator's patents concerning the berotralstat synthesis and its crystalline salt processes [3].
What are the clinical uses of Orladeyo (berotralstat)?
Orladeyo is approved for the prophylactic treatment of hereditary angioedema (HAE) attacks in adult and pediatric patients 12 years and older. It works by inhibiting plasma kallikrein, an enzyme involved in the HAE pathway that leads to swelling attacks [4].
How does berotralstat's mechanism of action work?
Berotralstat is a plasma kallikrein inhibitor. Plasma kallikrein, when overactive, can cleave high molecular weight kininogen to release bradykinin. Bradykinin is a potent vasodilator that contributes to the swelling characteristic of HAE attacks. By inhibiting plasma kallikrein, berotralstat reduces the production of bradykinin, thereby preventing HAE attacks [4].
What is the difference between berotralstat and other HAE treatments?
Orladeyo (berotralstat) is an oral, once-daily prophylactic treatment for HAE. Other HAE treatments may include on-demand therapies for acute attacks (such as icatibant, C1 esterase inhibitor concentrates, or FFP) or other prophylactic agents that may have different mechanisms of action or administration routes, such as intravenous or subcutaneous infusions [4].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/blog/what-are-drug-polymorphs-and-why-are-they-patented/
[3] https://www.drugpatentwatch.com/blog/understanding-patent-litigation-and-its-impact-on-drug-approvals/
[4] https://www.orladeyo.com/